Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.40 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.40 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16756807 | 1.00 | ALDH1A1 (0.46) | ALDH1A1POLBMAPK1GAANPSR1 | |
| SCHEMBL13607676 | 1.00 | ALDH1A1 (0.46) | ALDH1A1POLBMAPK1GAANPSR1 | |
| SCHEMBL6369092 | 1.00 | ALDH1A1 (0.46) | ALDH1A1POLBMAPK1GAANPSR1 | |
| SCHEMBL2692294 | 1.00 | ALDH1A1 (0.46) | ALDH1A1POLBMAPK1GAANPSR1 | |
| SCHEMBL16756809 | 1.00 | ALDH1A1 (0.46) | ALDH1A1POLBMAPK1GAANPSR1 | |
| SCHEMBL13455914 | 1.00 | ALDH1A1 (0.46) | ALDH1A1POLBMAPK1GAANPSR1 | |
| SCHEMBL2244419 | 0.90 | LGALS9 (0.44) | ALDH1A1POLBMAPK1GAANPSR1 | |
| SCHEMBL30620960 | 0.90 | ALDH1A1 (0.46) | ALDH1A1POLBMAPK1GAANPSR1 | |
| SCHEMBL4846095 | 0.90 | ALDH1A1 (0.46) | ALDH1A1POLBMAPK1GAANPSR1 | |
| SCHEMBL19326334 | 0.88 | ALDH1A1 (0.50) | ALDH1A1POLBMAPK1GAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112079891-A | Preparation method of antitumor drug gemcitabine hydrochloride | 苏州华鑫医药科技有限公司 | 2020-12-15 | — | — | CN | claimed |
| WO-2010029574-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF GEMCITABINE AND ITS INTERMEDIATES USING NOVEL PROTECTING GROUPS AND ION EXCHANGE RESINS | KANNAN VISHWANATH (IN) | 2010-03-18 | — | — | WO | claimed |
| EP-3334745-B1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11453697-B1 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2022-09-27 | — | — | US | disclosed |
| EP-3184112-B1 | SYNTHETIC INTERMEDIATE OF 1-(2-DEOXY-2-FLUORO-4-THIO-ß-D-ARABINOFURANOSYL)CYTOSINE | FUJIFILM CORP (JP) | 2020-12-23 | — | — | EP | disclosed |
| CN-112079891-A | Preparation method of antitumor drug gemcitabine hydrochloride | 苏州华鑫医药科技有限公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-112079891-A | Preparation method of antitumor drug gemcitabine hydrochloride | 苏州华鑫医药科技有限公司 | 2020-12-15 | — | — | CN | disclosed |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10570112-B2 | Synthetic intermediate of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine, synthetic intermediate of thionucleoside, and method for producing the same | FUJIFILM CORPORATION (JP) | 2020-02-25 | — | — | US | disclosed |
| EP-0577304-B1 | Stereoselective anion glycosylation process | LILLY CO ELI (US) | 1997-03-05 | — | — | EP | disclosed |
| US-5606048-A | REACTING A CONCENTRATED ALPHA- OR BETA-ANOMER ENRICHED 1-DEOXY-2,2-DIFLUOROCARBOHYDRATE OR 2-DEOXY-2-FLUOROCARBOHYDRATE WITH A MOLAR EQUIVALENT OF A NUCLEOBASE DERIVATIVE IN A HIGH BOILING INERT SOLVENT | ELI LILLY AND COMPANY (US) | 1997-02-25 | — | — | US | disclosed |
| US-5594124-A | REACTING ALPHA-ANOMER ENRICHED 2,2-DIFLUOROCARBOHYDRATE WITH AT LEAST THREE MOLAR EQUIVALENTS OF PROTECTED NUCLEOBASE IN LOW FREEZING INERT SOLVENT | ELI LILLY AND COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| US-5453499-A | Process for preparing alpha-anomer enriched 1-halo-2-deoxy-2,2-difluoro-D-ribofuranosyl derivatives | ELI LILLY AND COMPANY | 1995-09-26 | — | — | US | disclosed |
| US-5426183-A | Reacting 2'-deoxy-2(2)-(di)fluorocarbohydrate witha nucleobase in an inert solvent | ELI LILLY AND COMPANY (US) | 1995-06-20 | — | — | US | disclosed |
| US-5401838-A | Reaction of sulfonate furanose with nucleobase | ELI LILLY AND COMPANY (US) | 1995-03-28 | — | — | US | disclosed |
| US-5371210-A | Reacting alpha anomer enriched 2-deoxy-2,2-difluorocarbo-hydrate with nucleobase | ELI LILLY AND COMPANY (US) | 1994-12-06 | — | — | US | disclosed |
| EP-0577304-A1 | Stereoselective anion glycosylation process | ELI LILLY AND COMPANY (US) | 1994-01-05 | — | — | EP | disclosed |
| EP-0577303-A1 | Stereoselective glycosylation process | ELI LILLY AND COMPANY (US) | 1994-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | ALDH1A1 4183/4885POLB 354/4885MAPK1 1162/4885 |
| US-11453697-B1 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | ALDH1A1 4183/4885POLB 354/4885MAPK1 1162/4885 |
| US-10570112-B2 | Synthetic intermediate of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine, synthetic intermediate of thionucleoside, and method for producing the same | TYMS, TYMP, RRM2B | ALDH1A1 679/4885POLB 19/4885MAPK1 4374/4885 |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | ALDH1A1 4183/4885POLB 354/4885MAPK1 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.